The effect of Steroid on the outpatient treatment of Covid-19

Study the effect of Steroid on the outpatient treatment Covid-19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171219037964N2

Enrollment

Registered

2020-12-02

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: patients in this group will be treated by Prednisolone 50 milligram, once daily for 5 days. Intervention 2: Control group: patients in this group receive placebo, 1

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: definite case of Covid-19 age over 18 presented in day 5th-10th from the start of sign and symptoms

Exclusion criteria

Exclusion criteria: Severe cases with SpO2 under 90 Using an antiviral in previous two weeks Previous infection with covid-19 Using an steroid in previous two weeks Being under treatment with steroid Previous allergic to Steroid Pregnancy Lactating Immunosupressive state

Design outcomes

Primary

Measure	Time frame
Treatment failure. Timepoint: days 3, 7, 14, 21, 28 from the start of treatment. Method of measurement: interview with patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Amra

Esfahan University of Medical Sciences

Amra@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026